Biomind Labs CEO Alejandro Antalich tells Proactive the Toronto, Canada-based group was recently granted approval by the Brazilian Institutional Review Board to begin its Phase II clinical study evaluating its formulation of DMT for treatment-resistant depression.
Compound DMT
Visit article
Category Press Release
Country Brazil